November 24, 2015
Recommended Topic Related To:


"The U.S. Food and Drug Administration today approved the Argus II Retinal Prosthesis System, the first implanted device to treat adult patients with advanced retinitis pigmentosa (RP). The device, which includes a small video camera, transmitter "...




Although no human data are available, electrolyte imbalance, development of an acidotic state, and possible nervous system efiects may occur following an oral overdose of brinzolamide. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored.

Very limited information exists on accidental ingestion of brimonidine in adults; the only adverse event reported to date has been hypotension. Symptoms of brimonidine overdose have been reported in neonates, infants, and children receiving brimonidine as part of medical treatment of congenital glaucoma or by accidental oral ingestion. Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be maintained.



SIMBRINZA is contraindicated in patients who are hypersensitive to any component of this product.

Neonates And Infants (under the age of 2 years)

SIMBRINZA is contraindicated in neonates and infants (under the age of 2 years) [see Use in Specific Populations].

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 11/23/2015


Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.